๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
SeaStar Medical Holding Corporation (ICU)
NASDAQ: ICU ยท Real-Time Price ยท USD
0.9350
-0.1150 (-10.95%)
At close: Nov 20, 2026, 4:00 PM EST
0.8919
-0.0431 (-4.61%)
After-hours: Nov 20, 2026, 7:44 PM EST

SeaStar Medical Holding Earnings Call Transcripts

Fiscal Year 2026

  • Q3 revenue rose 247% YoY as QUELIMMUNE adoption grew, while NEUTRALIZE-AKI enrollment reached 251 of 339 and completion moved to mid-2027. Cash was $4M at quarter-end, excluding $3.3M in October warrant proceeds.

  • At the H.C. Wainwright conference, a novel therapy for organ failure was highlighted, showing strong pediatric results and advancing pivotal adult trials. The company targets significant market expansion, with regulatory and reimbursement milestones expected by 2027.

  • QUELIMMUNE revenue grew 82% year-over-year in Q2 2026, with adoption doubling among top pediatric hospitals. NEUTRALIZE-AKI trial for adult AKI is progressing, with enrollment on track and regulatory milestones supported by FDA designations.

  • SCD therapy targets hyperinflammation at its source, showing strong survival benefits and no device-related adverse events in pediatric AKI, with a robust pipeline expanding into adult and cardiorenal indications. Commercialization is advancing, supported by FDA approvals, CMS reimbursement, and a clean financial position.

  • QUELIMMUNE net revenue grew 69% year-over-year in Q1 2026, with seven new hospital adoptions and strong gross margins. The NEUTRALIZE-AKI pivotal trial for adult AKI is progressing, and the SAVE Registry reached 50-patient enrollment. Cash reserves increased to $9.3 million.

  • The session highlighted a novel device-based approach to treating hyperinflammation, with strong pediatric results and ongoing adult trials. Key milestones include expanding hospital adoption, advancing pivotal studies, and pursuing regulatory and commercial growth.

  • Biotech Showcase 2026

    Focused on stopping organ failure via a unique device platform, the company has launched QUELIMMUNE for pediatric AKI, showing strong survival benefits and cost savings. Adult pivotal studies are underway, with a robust pipeline and financial health supporting expansion.

Fiscal Year 2025

Fiscal Year 2024

  • First FDA-approved product QUELIMMUNE launched for pediatric AKI, with growing hospital adoption and initial revenues. NEUTRALIZE-AKI pivotal trial for adult AKI is progressing, with interim analysis expected mid-2025. Multiple Breakthrough Device designations and strong financial management position the company for significant market expansion.